These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30224159)

  • 1. Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
    Béreau M; Fleury V; Bouthour W; Castrioto A; Lhommée E; Krack P
    Rev Neurol (Paris); 2018 Nov; 174(9):653-663. PubMed ID: 30224159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impulse Control and Related Disorders in Parkinson's Disease.
    Weintraub D; Claassen DO
    Int Rev Neurobiol; 2017; 133():679-717. PubMed ID: 28802938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Punding in non-demented Parkinson's disease patients: Relationship with psychiatric and addiction spectrum comorbidity.
    Pettorruso M; Fasano A; De Risio L; Ricciardi L; Di Nicola M; Martinotti G; Janiri L; Bentivoglio AR
    J Neurol Sci; 2016 Mar; 362():344-7. PubMed ID: 26944176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurobiology and clinical features of impulse control failure in Parkinson's disease.
    Béreau M; Krack P; Brüggemann N; Münte TF
    Neurol Res Pract; 2019; 1():9. PubMed ID: 33324875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease management and impulse control disorders: current state and future perspectives.
    Vitale C; Amboni M; Erro R; Picillo M; Pellecchia MT; Barone P; Trojano L; Santangelo G
    Expert Rev Neurother; 2019 Jun; 19(6):495-508. PubMed ID: 31148487
    [No Abstract]   [Full Text] [Related]  

  • 6. Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors.
    Sierra M; Carnicella S; Strafella AP; Bichon A; Lhommée E; Castrioto A; Chabardes S; Thobois S; Krack P
    J Parkinsons Dis; 2015; 5(3):625-36. PubMed ID: 25870025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
    Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
    Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impulsive-compulsive syndrome in Parkinson's disease].
    Nikitina AV; Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.
    Ghadery C; Valli M; Mihaescu A; Strafella R; Navalpotro I; Kim J; Strafella AP
    Int Rev Neurobiol; 2018; 141():365-404. PubMed ID: 30314604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictors and modifiers of impulse control disorders in Parkinson`s disease].
    Sapronova MR; Shnayder NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11):145-156. PubMed ID: 28635753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy.
    Lopez AM; Weintraub D; Claassen DO
    Semin Neurol; 2017 Apr; 37(2):186-192. PubMed ID: 28511259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impulse control disorders in Parkinson's disease patients with RLS: a cross sectional-study.
    Marques A; Figorilli M; Pereira B; Derost P; Debilly B; Beudin P; Vidal T; Durif F; Fantini ML
    Sleep Med; 2018 Aug; 48():148-154. PubMed ID: 29913341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Corvol JC
    Bull Acad Natl Med; 2014 Oct; 198(7):1297-307; discussion 1307-8. PubMed ID: 27120903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Catalan MJ; Molina-Arjona JA; Mir P; Cubo E; Arbelo JM; Martinez-Martin P;
    J Neurol; 2018 Jun; 265(6):1279-1287. PubMed ID: 29557989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Delpont B; Lhommée E; Klinger H; Schmitt E; Bichon A; Fraix V; Castrioto A; Quesada JL; Pélissier P; Kistner A; Carnicella S; Lüscher C; Broussolle E; Pollak P; Thobois S; Krack P
    Mov Disord; 2017 Nov; 32(11):1566-1573. PubMed ID: 28737225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions.
    Ramirez-Zamora A; Gee L; Boyd J; Biller J
    Expert Rev Neurother; 2016; 16(4):389-99. PubMed ID: 26923084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease-related disorders in the impulsive-compulsive spectrum.
    Wolters ECh; van der Werf YD; van den Heuvel OA
    J Neurol; 2008 Sep; 255 Suppl 5():48-56. PubMed ID: 18787882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in impulse control behaviours of Parkinson's disease.
    Zurowski M; O'Brien JD
    Curr Opin Neurol; 2015 Aug; 28(4):387-92. PubMed ID: 26110803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impulse control symptoms in patients with Parkinson's disease: The influence of dopaminergic agonist.
    Vargas AP; Vaz LS; Reuter A; Couto CM; Costa Cardoso FE
    Parkinsonism Relat Disord; 2019 Nov; 68():17-21. PubMed ID: 31621612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.